Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

LG Chem Forms IO Collaboration Worth Up to $1 Billion with Cue Biopharma

publication date: Nov 12, 2018

LG Chem Life Sciences of South Korea formed a nearly $1 billion IO collaboration with Cue Biopharma, a Boston area immunotherapy company. LG will have Asia rights, including China, to three Cue IO candidates, all of them in preclinical development. LG will provide its biologics manufacturing expertise to the portfolio. LG paid an unspecified upfront fee, invested $5 million in Cue, and will be responsible for up to $400 million in milestones. In addition, LG will have a two-year option on global rights to another Cue candidate in a deal worth over $500 million in fees and potential milestones. More details...

Stock Symbol: (NSDQ: CUE)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.